Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2013 | 11:03am CET

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
05:26a China's bitcoin exchanges, eyed by regulators, slap on trading fees
05:25a MRSK VOLGI : On the new year holidays power supply was strictly controlled by IDGC of Volga, PJSC
05:23a NISSAN MOTOR : Kyodo Top12 News
05:20a BINGO : Date of board meeting
05:16aDJNEWS HIGHLIGHTS : Top Global Markets News of the Day
05:16aDJNEWS HIGHLIGHTS : Top Company News of the Day
05:15a EVERBRIGHT SECURITIES : EB Securities 2016 profit down 59.8% to Rmb3.07bn
05:13a TRIPPLE GEE AND : blames poor performance on Naira depreciation
05:10aDJCEE MORNING BRIEFING : Hungary Central Bank Chairman Speaks
05:10a NOIDA TOLL BRIDGE : SC to hear NTBCL's plea on DND flyway
Latest news
Advertisement
Hot News 
-11.28%Bristol-Myers lung cancer delay slams shares, keeps Merck in lead
-2.18%GENERAL ELECTRIC : Nason, former Treasury official, being vetted for Fed role - sources
2.24%IBM revenue fall dims upbeat profit forecast
2.45%Rockwell Collins Confident on Jet Ramp -- 2nd Update
12.40%SYNTHOMER : Chemicals maker Synthomer sees 2016 profit ahead of estimates
Most Read News
08:57p SAMSUNG ELECTRONICS : Elec says battery defects caused Note 7 fires
09:30p TASMAN RESOURCES : EdenCrete added to GDOT Qualified Products List
06:10p SLATER & GORDON : Don’t get caught out chucking a sickie this Australia Day weekend
07:16pDJSINGAPORE EXCHANGE : to Launch LNG Index
08:55p FRASER AND NEAVE : Announcement pursuant to Rule 704(17)(b)
Most recommended articles
01/17DJS&P 500, Nasdaq Futures -- Technical Analysis
11:10pDJCEE MORNING BRIEFING : Hungary Central Bank Chairman Speaks
11:10pDJOil Prices Tick Higher as OPEC Deal Drains Supply, Dollar Slides
10:40pDJSAMSUNG ELECTRONICS : Blames Galaxy Note 7 Overheating on Problems at Suppliers -- Update
10:30p NIKKEI : Dollar slips after Trump's protectionist address, Asia shares resilient